Core Viewpoint - Tianjin Development (00882.HK) announced that Lifesun Pharmaceutical (002393.SZ) achieved a revenue of 1.007 billion yuan in the first three quarters of 2025, reflecting a year-on-year decrease of 1.61% while net profit attributable to shareholders increased by 119.05% to 370 million yuan [1] Financial Performance - Lifesun Pharmaceutical's revenue for the first three quarters of 2025 was 1.007 billion yuan, down 1.61% year-on-year [1] - The net profit attributable to shareholders reached 370 million yuan, showing a significant increase of 119.05% compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 127 million yuan, which represents a year-on-year growth of 19.21% [1] - Basic earnings per share were reported at 1.44 yuan [1]

Core Viewpoint - Tianjin Development (00882) announced that its indirect non-wholly-owned subsidiary, Tianjin Lisheng Pharmaceutical (002393), reported a total revenue of 1.007 billion yuan for the nine months ending September 30, 2025, representing a year-on-year decrease of 1.61% while the net profit attributable to the parent company increased by 119.05% to 371 million yuan, with basic earnings per share of 1.44 yuan [1] Financial Performance - Total revenue for Tianjin Lisheng Pharmaceutical for the nine months was 1.007 billion yuan, down 1.61% year-on-year [1] - Net profit attributable to the parent company reached 371 million yuan, marking a significant increase of 119.05% compared to the previous year [1] - Basic earnings per share stood at 1.44 yuan [1]

Core Viewpoint - Tianjin Development (00882) reported a mixed financial performance for its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd., with a slight decline in revenue but a significant increase in net profit [1] Financial Performance - Total revenue for the nine months ending September 30, 2025, was 1.007 billion yuan, representing a year-on-year decrease of 1.61% [1] - Net profit attributable to the parent company's owners was 371 million yuan, showing a year-on-year increase of 119.05% [1] - Basic earnings per share stood at 1.44 yuan [1]

Group 1 - The company announced the election of Ms. Wang Qian as the employee director of the eighth board of directors [2] - The term of the newly elected director will last until the end of the eighth board's term [2]

（文章来源：证券日报） 证券日报网讯 10月23日晚间，力生制药发布公告称，公司第七届董事会任期已届满。根据有关规定， 公司将按照相关程序进行董事会换届选举。公司于2025年10月22日召开第七届董事会第五十三次会议审 议通过了《关于选举第八届董事会非独立董事的议案》《关于选举第八届董事会独立董事的议案》，经 公司第七届董事会提名委员会审查，公司董事会同意提名张平先生、滕飞先生、王福军先生、段爽女士 和卢小曼女士为第八届董事会非独立董事候选人；同意提名雷英女士、魏东芝先生和张梅女士为公司第 八届董事会独立董事候选人。 ...

Core Viewpoint - Lisheng Pharmaceutical reported a slight decline in revenue for the first three quarters of 2025, but a significant increase in net profit and earnings per share, indicating strong profitability despite revenue challenges [1] Financial Performance - Revenue for the first three quarters of 2025 was approximately 1.007 billion yuan, a year-on-year decrease of 1.61% [1] - Net profit attributable to shareholders was about 371 million yuan, reflecting a year-on-year increase of 119.05% [1] - Basic earnings per share reached 1.44 yuan, up 118.18% year-on-year [1] Market Position - As of the report date, Lisheng Pharmaceutical's market capitalization stood at 6.1 billion yuan [1]

2025年1至6月份，力生制药的营业收入构成为：制药业占比100.0%。 每经AI快讯，力生制药（SZ 002393，收盘价：23.65元）10月23日晚间发布公告称，公司第七届第五十 三次董事会会议于2025年10月22日以通讯表决方式召开。会议审议了《关于选举公司第八届董事会独立 董事的议案》等文件。 每经头条（nbdtoutiao）——四次登上央视，知名大佬"消失"5年，我们在水果仓库找到了他！从月薪 5000到千亿市值公司联席总裁，他45岁再创业 截至发稿，力生制药市值为61亿元。 （记者 王瀚黎） ...

格隆汇10月23日丨力生制药(002393.SZ)公布三季度报告，前三季营业收入10.07亿元，同比下降1.61%， 归属于上市公司股东的净利润3.7亿元，同比增长119.05%，归属于上市公司股东的扣除非经常性损益的 净利润1.27亿元，同比增长19.21%。 ...

智通财经APP讯，力生制药(002393.SZ)披露2025年第三季度报告，公司前三季度实现营收10.07亿元， 同比下降1.61%;归属于上市公司股东的净利润3.71亿元，同比增长119.05%;扣非净利润1.27亿元，同比 增长19.21%;基本每股收益1.44元。 ...

力生制药公告，第三季度营收为2.76亿元，下降1.20%；净利润为2781.64万元，下降58.42%。前三季度 营收为10.07亿元，下降1.61%；净利润为3.71亿元，增长119.05%。 ...